<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210910052428N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-12</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>"Hydrodilatation in adhesive capsulitis",  " Intra-articular corticosteroid in adhesive capsulitis"</public_title>
      <acronym></acronym>
      <scientific_title>A Comparative study between intra-articular corticosteroid injection and ultrasound-guided hydrodilatation in patients with shoulder adhesive capsulitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58893</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To match patients in the intervention and control groups,
patients are randomly assigned to one of two treatment
groups. The random allocation method in this study will
be the permutation blocks randomization method with 4
samples in each block and a random list of data will be
obtained by using Random Allocation software. We will
have two lists of 24 patients, including the two
intervention and control groups, at random. For
concealment, method of random sequencing is given to
another person who is unaware of the research process,
and the questionnaires are completed by a person
unaware of the division of groups, Blinding description: Participants in study Participant: in this study, we does not have the ability to blind the participant because the participant is aware of
receiving each intervention. Clinical care giver: we teach
the caregiver how to complete the questionnaire. This
person is not aware of receiving patient’s intervention.
Researcher: this study does not have the ability to blind
the researcher due to performing both interventions by
himself and being aware of receiving the kind of
intervention in each group. The outcome assessor of the
complete questionnaires is given to a person who is not
aware of the intervention performed and he/she is asked
to determine the level of performance in each person
according to the questionnaires. Data analyzer:
questionnaire are finally given to a person to review the
information. This person does not know any of the steps
of the work and the way of classification in which the
intervention performed.</study_design>
      <phase>3</phase>
      <hc_freetext>Shoulder adhesive capsulitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: injection of normal saline 0.9% with 25cc/sec rate in prevention of capsular rupture due to large amount injection, with injection of 3cc lidocaine under sterile circumstance and with usage of 20 cc syringe in a condition that syringe be parallel to ultrasound probe in semi oblique plane from posterior aspect of shoulder will be done. Intervention 2: Control group: injection of 1 cc methylprednisolone 40 mg/ml plus 1cc lidocaine 2% and 3cc normal saline in a situation that patient is in a prone position and under sterile circumstance and with usage of 20 cc syringe in a condition that syringe be parallel to ultrasound probe in semi oblique plane from posterior aspect of shoulder will be done.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All available data can be shared after making people
unidentifiable.

When:
Start access period one year after publishing the results.

To whom:
Everyone can access to this information.

Conditions:
If the information in this study helps to improve the
science process.

Where to obtain:
Dr.vahide nadgaran
v.nadgaran@gmail.com
+989171090973

How to obtain:
After sending the desired message, all authors of the
study will be consulted all information will be sent within
a maximum of three weeks if permitted.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Vahide Nadgaran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>5/1 Alley, South Eghbal lahoori Ave,  Ostad Shahriar Ave, Moddaress Blvd</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7157748857</zip>
        <telephone>+98 71 3722 2038</telephone>
        <email>v.nadgaran@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Vahide Nadgaran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>5/1 Alley, South Eghbal lahoori Ave, Ostad Shahriar Ave, Moddaress Blvd</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7157748857</zip>
        <telephone>+98 71 3722 2038</telephone>
        <email>v.nadgaran@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Presence of pain and shoulder range of motion limitation more than 30 degree in more than two motion plane
Presence of pain and shoulder range of motion limitation more than one month</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Shoulder pain after cerebrovascular attack in paretic side
Patients with severe glenohumeral joint osteoarthritis
Patients with complete rotator cuff ligaments tear
Immune deficiency
Fracture in humerus bone or scapula
Pregnant women
Patients with cancer
History of allergy and reaction due in use drugs
Shoulder joint rheumatoid arthritis
Severe depression
Uncontrolled diabetes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M75.00</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Adhesive capsulitis of unspecified shoulder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: injection of normal saline 0.9% with 25cc/sec rate in prevention of capsular rupture due to large amount injection, with injection of 3cc lidocaine under sterile circumstance and with usage of 20 cc syringe in a condition that syringe be parallel to ultrasound probe in semi oblique plane from posterior aspect of shoulder will be done.</i_keyword>
      <i_keyword>Control group: injection of 1 cc methylprednisolone 40 mg/ml plus 1cc lidocaine 2% and 3cc normal saline in a situation that patient is in a prone position and under sterile circumstance and with usage of 20 cc syringe in a condition that syringe be parallel to ultrasound probe in semi oblique plane from posterior aspect of shoulder will be done.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>" Score of pain in visual analoge scale questionnaire" , " Shoulder disability score in shoulder pain and disability index questionnaire". Timepoint: " Measurement of shoulder range of motion  and pain score at the beginning, 2, 4 and 8 weeks after shoulder injection". Method of measurement: Visual analog scale and shoulder pain and disability index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Shoulder Pain. Timepoint: Before intervention; two weeks, four weeks and  eight weeks later. Method of measurement: Visual Analogue Scale; Shoulder Pain And Disability Index.</sec_outcome>
      <sec_outcome>Shoulder range of motion. Timepoint: Before intervention; two weeks, four weeks and eight weeks later. Method of measurement: With usage of goniometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-08-30</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>No 5/1alley, South eghbale lahoori Ave, Ostad shahriar Ave, Moddaress Blvd Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
